Neutropenia Biologic Drug Treatment Global Market Report 2022: Filgrastim, Pegfilgrastim, Lenograstim, Lipegfilgrastim, Sargramostim, Antibiotic Drugs, G-CSF, Antifungal Drugs - ResearchAndMarkets.com

·5 min read

DUBLIN, May 17, 2022--(BUSINESS WIRE)--The "Neutropenia Biologic Drug Treatment Global Market Report 2022: By Drug, By Treatment, By Distribution" report has been added to ResearchAndMarkets.com's offering.

The global neutropenia biologic drug treatment market is expected to grow from $10.22 billion in 2021 to $11.26 billion in 2022 at a compound annual growth rate (CAGR) of 10.2%.

The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $14.78 billion in 2026 at a CAGR of 7.0%.

Major players in the neutropenia biologic drug treatment market are Teva Pharmaceutical, Amgen, Sanofi, Mylan, Kyowa Kirin, Baxter International, CVS Health Corp., Novartis, Spectrum Pharmaceuticals, and Partner Therapeutics.

The neutropenia biologic drug treatment market consists of sales of biologics used for the treatment of neutropenia and related services by entities (organizations, sole traders and partnerships) that produce biologics for neutropenia treatment. Neutropenia is a clinical condition characterized by a decrease in neutrophil count in the blood, resulting in a higher risk of developing serious infections.

A neutrophil is a type of white blood cell, which helps in fighting infections. The major causes of neutropenia include cancer chemotherapy, infections, bone marrow disorders, autoimmune disorders, and the use of specific drugs. The market consists of revenue generated by the company's manufacturing the neutropenia biologic drugs by the sales of these products.

The main types of drugs in neutropenia biologic drug treatment are filgrastim, pegfilgrastim, lenograstim, lipegfilgrastim and sargramostim. Filgrastim is a recombinant form of granulocyte colony-stimulating protein which is given as an injection to boost neutrophil production after chemotherapy. The different types of treatments include antibiotic drugs, granulocyte-colony-stimulating factor (G-CSF), antifungal drugs, others and distributed through various channels such as retail pharmacies, hospital pharmacies, online pharmacies.

The rise in the number of cancer cases across the globe is likely to contribute to the growth of the neutropenia biologic drugs market. Due to a growing cancer incidence and an increase in the number of people opting for chemotherapy, there has been an increasing incidence in the number of people suffering from neutropenia.

According to a 2019 study by Cancer.net, around 50% of the people with cancer who are undergoing chemotherapy have some level of neutropenia. According to the American Cancer Society, there were 1.7 million new cases and 0.6 million cancer deaths in 2019 in the USA. Therefore, the rise in cancer incidence rate globally is anticipated to boost the demand for the neutropenia biologic drug treatment market over the forthcoming years.

The introduction of biosimilars as a result of patent expiry is expected to hamper the growth of the neutropenia biologic drug treatment market. Biosimilar is a therapeutic agent, which has high similarity with the original biological product in action but is available at a lower cost than the cost of the original product. Biosimilars are mostly priced at 70% of the branded drug price and are likely to replace expensive branded drugs.

For instance, Novartis AG launched a biosimilar drug, Zarxio, which has substituted Amgen's branded biologic drug, Neupogen. These less expensive alternatives increase competition in the biologics market putting downward pressure on pricing and market value growth.

Companies in the neutropenia biologic drug treatment market are increasingly investing in developing novel drug delivery systems to improve the therapeutic response of the drug and increase its efficacy. Novel drug delivery systems allow the delivery of a very high dose of drugs directly into the neutrophils, while the systemic dose remains low, thus disallowing side-effects.

Key Topics Covered:

1. Executive Summary

2. Neutropenia Biologic Drug Treatment Market Characteristics

3. Neutropenia Biologic Drug Treatment Market Trends And Strategies

4. Impact Of COVID-19 On Neutropenia Biologic Drug Treatment

5. Neutropenia Biologic Drug Treatment Market Size And Growth

5.1. Global Neutropenia Biologic Drug Treatment Historic Market, 2016-2021, $ Billion

5.1.1. Drivers Of The Market

5.1.2. Restraints On The Market

5.2. Global Neutropenia Biologic Drug Treatment Forecast Market, 2021-2026F, 2031F, $ Billion

5.2.1. Drivers Of The Market

5.2.2. Restraints On the Market

6. Neutropenia Biologic Drug Treatment Market Segmentation

6.1. Global Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

  • Filgrastim

  • Pegfilgrastim

  • Lenograstim

  • Lipegfilgrastim

  • Sargramostim

6.2. Global Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

  • Antibiotic Drugs

  • Granulocyte-Colony-Stimulating Factor (G-CSF)

  • Antifungal Drugs

  • Others

6.3. Global Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

  • Retail Pharmacies

  • Hospital Pharmacies

  • Online Pharmacies

7. Neutropenia Biologic Drug Treatment Market Regional And Country Analysis

7.1. Global Neutropenia Biologic Drug Treatment Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

7.2. Global Neutropenia Biologic Drug Treatment Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

Companies Mentioned

  • Teva Pharmaceutical

  • Amgen

  • Sanofi

  • Mylan

  • Kyowa Kirin

  • Baxter International

  • CVS Health Corp.

  • Novartis

  • Spectrum Pharmaceuticals

  • Partner Therapeutics

  • Pfizer

  • Myelo Therapeutics

  • Cellerant Therapeutics

  • Sandoz (Subsidary of Novartis AG)

  • BeyondSpring Pharmaceuticals

  • Enzychem Lifesciences Corporation

  • Tianjin SinoBiotech

  • S&D Pharma SK s.r.o.

  • Generon (Shanghai) Corporation Ltd.

  • PhytoHealth Corporation

  • Dong-A ST Co.

For more information about this report visit https://www.researchandmarkets.com/r/hvhrdr

View source version on businesswire.com: https://www.businesswire.com/news/home/20220517005788/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting